F4/80 inhibits osteoclast differentiation via downregulation of nuclear factor of activated T cells, cytoplasmic 1
Authors:
- 16 February 2017
- journal article
- research article
- Published by Springer Nature in Archives of Pharmacal Research
- Vol. 40 (4) , 492-499
Abstract
Osteoclastogenesis is an essential process in bone metabolism, which can be induced by RANKL stimulation. The F4/80 glycoprotein is a member of the EGF-transmembrane 7 (TM7) family and has been established as a specific cell-surface marker for murine macrophages. This study aimed to identify the role of F4/80 in osteoclastogenesis. Using mouse bone marrow-derived macrophages (BMMs), we observed that the mRNA level of F4/80 was dramatically reduced as these cells differentiated into osteoclasts. Furthermore, osteoclastogenesis was decreased in F4/80high BMMs compared to F4/80−/low BMMs. The inhibitory effect of F4/80 was associated with decreased expression of nuclear factor of activated T cells, cytoplasmic 1 (NFATc1). Ectopic overexpression of a constitutively active form of NFATc1 rescued the anti-osteoclastogenic effect of F4/80 completely, suggesting that the anti-osteoclastogenic effect of F4/80 was mainly due to reduction in NFATc1 expression. As an underlying mechanism, we demonstrated that the presence of F4/80 abrogated the effect of RANKL on the phosphorylation of CREB and activated the expression of IFN-β, which are restored by cyclic AMP. Collectively, our results demonstrate that the presence of F4/80 suppresses RANKL-induced osteoclastogenesis by impairing the expression of NFATc1 via CREB and IFN-β. Therefore, F4/80 may hold therapeutic potential for bone destructive diseases.Keywords
Funding Information
- National Research Foundation of Korea (2014M1A3A3A02034917)
- Ministry of Health and Welfare (HI14C24470000)
This publication has 23 references indexed in Scilit:
- The Role of the Transcription Factor CREB in Immune FunctionThe Journal of Immunology, 2010
- Parathyroid hormone treatment for osteoporosisCurrent Opinion in Endocrinology, Diabetes and Obesity, 2008
- Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease OutcomesThe NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 TrialJAMA, 2006
- OSTEOIMMUNOLOGY: Interplay Between the Immune System and Bone MetabolismAnnual Review of Immunology, 2006
- Ghrelin against alendronate-induced gastric damage in ratsJournal of Endocrinology, 2005
- The macrophage F4/80 receptor is required for the induction of antigen-specific efferent regulatory T cells in peripheral toleranceJournal of Experimental Medicine, 2005
- Genetic regulation of osteoclast development and functionNature Reviews Genetics, 2003
- RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-βNature, 2002
- Bone Resorption by OsteoclastsScience, 2000
- Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and ActivationCell, 1998